Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00409747 · ClinicalTrials.gov registry record · Phase 4

Minocycline to Treat Childhood Regressive Autism

A Phase 4 study of Autism and Minocycline, sponsored by National Institute of Mental Health (NIMH).

Completed
Registry status
Phase 4
Development phase
11
Enrollment target
2
Study locations

NCT00409747 is a Phase 4 study of Autism and Minocycline that has completed, run by National Institute of Mental Health (NIMH). The registered enrollment target is 11 participants, below the 183-participant average among 104 other Autism trials with a reported enrollment target (94% lower). The trial reports 2 study locations across 2 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00409747, a Phase 4 study of Autism and Minocycline, has completed, sponsored by National Institute of Mental Health (NIMH).

COMPLETED
Registry status
Phase 4
Development phase
11 participants
Enrollment target
2
Study locations

Study Summary

There is a subgroup of children with autism that appears to develop typically for a period of time, and then loses social or language skills, or regresses. A recent study by Vargas and co-workers at Johns Hopkins has demonstrated that this regressive type of autism is associated with chronic brain inflammation as shown by an abnormal production of inflammatory cytokines among other abnormalities. This present study will test the effectiveness of minocycline, an antibiotic with anti-inflammatory properties, in treating regressive autism. Although behavioral therapies have improved some symptoms of autism, there are no medical treatments for the disorder, and many children have ongoing behavioral difficulties. A medicine with anti-inflammatory properties may be beneficial for children with regressive autism. This will be an open-label trial, meaning all children in this study will receive minocycline. They will also receive vitamin B6 to reduce the possible chance of side effects of the minocycline. Children ages 3 to 12 with regressive autism may be eligible for this study. The children will take minocycline and vitamin B6 daily for 6 months. Prior to starting the medication and vitamin B6, children will receive a comprehensive diagnostic assessment for autism as well as a physical examination, medical history, and laboratory tests. Children will then receive ongoing assessments to monitor their behavior, communication, language skills, and medical issues at 2 weeks, and at 1, 2, 4, 6, and 12 months. Children who respond to the treatment will receive an additional 3 months of minocycline and vitamin B6.

Interventions

  • DRUG Minocycline

Study Locations (2)

District of Columbia

  • Childrens National Medical Center - Washington D.C.

Maryland

  • National Institutes of Health Clinical Center, 9000 Rockville Pike - Bethesda

Trial Details

FieldValue
Enrollment Target 11 participants
Start Date 2006-11
Est. Completion 2011-04
Phase Phase 4

What the Registry Record Tells You About NCT00409747

The ClinicalTrials.gov registry entry for NCT00409747 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 11 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 183-participant average among 104 other Autism trials with a reported enrollment target (94% lower). The listed sponsor is National Institute of Mental Health (NIMH), which has 343 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Autism appearing as the primary indexed condition, and to 1 intervention - of which Minocycline is the first listed.

NCT00409747 reports 2 study locations spanning 2 distinct geographic areas - top geographies include District of Columbia, Maryland.

Frequently Asked Questions

What is clinical trial NCT00409747 about?

NCT00409747 is a clinical study titled "Minocycline to Treat Childhood Regressive Autism". There is a subgroup of children with autism that appears to develop typically for a period of time, and then loses social or language skills, or regresses. A recent study by Vargas and co-workers at Johns Hopkins has demonstrated that this regressive type of autism is associated with chronic brain i...

What is the current status of trial NCT00409747?

This trial is currently completed. It is a Phase 4 study. The enrollment target is 11 participants. The study started on 2006-11. Estimated completion is 2011-04.

What conditions does trial NCT00409747 study?

This clinical trial studies the following conditions: Autism, Minocycline, Regressive Autism.

What interventions are being tested in trial NCT00409747?

The interventions under investigation include: Minocycline (DRUG).

Who is sponsoring clinical trial NCT00409747?

This trial is sponsored by National Institute of Mental Health (NIMH), which has 343 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00409747 being conducted?

This trial has 2 study locations across District of Columbia, Maryland. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Autism

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.